Original articleOphthalmic Findings of Rosai-Dorfman Disease
Section snippets
Methods
This study complied with the Health Insurance Portability and Accountability Act and was approved by the Mayo Clinic Institutional Review Board. Mayo Clinic electronic records were searched for all patients with RDD diagnosis from January 1, 1992 to December 31, 2016. The search terms used were “Rosai-Dorfman disease” and “sinus histiocytosis with massive lymphadenopathy.” A total of 158 patients were narrowed by manual chart review of clinical notes and pathology reports to 76 patients with
Results
During a 24-year period at Mayo Clinic, the terms “Rosai-Dorfman disease” or “sinus histiocytosis with massive lymphadenopathy” appeared in the medical record of 158 patients. Of these 158 patients, 76 (48.1%) had a diagnosis of RDD, of which 67 patients had tissue confirmation with biopsy performed at Mayo Clinic, 6 patients had tissue confirmation with biopsy done elsewhere, and 3 patients had only clinically presumed RDD diagnosis without tissue confirmation.
In the other 82 patients (51.9%),
Discussion
Over a period of 24 years at Mayo Clinic, 76 patients were diagnosed with RDD. Patients with other neoplastic, histiocytic, and infectious disorders may have initially been diagnosed and confused with RDD, particularly patients with Erdheim-Chester disease, B-cell lymphoma, Hodgkin lymphoma, and xanthogranuloma. Notably, many patients in whom the diagnosis of RDD was considered or initially given ultimately did not receive a conclusive diagnosis for their condition.
Eight of the 76 patients
References (31)
- et al.
The ophthalmologic manifestations of sinus histiocytosis with massive lymphadenopathy
Am J Ophthalmol
(1979) - et al.
Immunophenotypic characterization of the cell infiltrate in five cases of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease)
Hum Pathol
(1992) - et al.
BRAF V600E mutation-specific antibody: a review
Semin Diagn Pathol
(2015) - et al.
Recurrent BRAF mutations in Langerhans cell histiocytosis
Blood
(2010) - et al.
Erdheim-Chester disease: a systematic review
Crit Rev Oncol Hematol
(2015) - et al.
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
Blood
(2012) - et al.
Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation
Blood
(2013) - et al.
Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation
Blood
(2014) - et al.
Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease
Mod Pathol
(2017) - et al.
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Blood
(2016)
Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity
Arch Pathol
Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity
Semin Diagn Pathol
Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): imaging manifestations in the head and neck
AJR Am J Roentgenol
A case of Rosai-Dorfman disease involving the lacrimal gland in an elderly patient
Orbit
A case of orbital Rosai-Dorfman disease responding to radiotherapy
J Pediatr Hematol Oncol
Cited by (21)
Ophthalmologic Involvement in Adults with Histiocytic Disorders: Clinical Presentation and Treatment Outcomes
2023, OphthalmologyCitation Excerpt :These data were cross-referenced against existing institutional databases of histiocytic disorders to ensure full capture. Four patients with RDD were included in a previous study evaluating ophthalmologic involvement of RDD but not in comparison with the other subtypes,4 and data from other patients have been presented in another article6 from this group without a specific focus on ophthalmologic involvement. Medical records of patients with a histiocytic disorder were reviewed by a neurologist (S.A.B.) for demographic, clinical, and laboratory data, and subsequently confirmed by an ophthalmologist (M.T.B.) blinded to histiocytic diagnosis.
Cyclin D1 Expression and Molecular Genetic Findings in Periocular Histiocytoses and Neoplasms of Macrophage-Dendritic Cell Lineage
2022, American Journal of OphthalmologyCitation Excerpt :All 7 lesions negative for BRAF V600E mutation were also negative for BRAF V600E by immunohistochemistry. Histiocytoses and neoplasms of macrophage-dendritic cell lineage can cause significant ocular and systemic morbidity.2-6 The discovery of the importance of MAPK signaling in pathogenesis of histiocytoses and neoplasms of histiocytic-dendritic cell lineage has transformed the approach to diagnosis and management of these lesions.1,7,18-20
Cataract surgery in a case of Rosai-Dorfman disease with proptosis
2018, Journal of Cataract and Refractive SurgeryRosai–Dorfman disease as chronic bilateral granulomatous anterior uveitis: A case report
2024, SAGE Open Medical Case ReportsOrbital histiocytosis and fibrohistiocytosis: the clinicopathological characteristics of 117 patients, over a decade of experience
2023, International OphthalmologyCutaneous and ocular persistent yellowish plaques: A clinicopathological challenge
2023, Clinical and Experimental Dermatology
Supplemental Material available at AJO.com.